Lack of effect of TNFα blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies
Lack of effect of TNFα blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies
复制标题
TNFα 阻断疗法对自身免疫性疾病患者循环脂联素水平缺乏影响：两项独立前瞻性研究的结果
DOI：
10.1136/ard.2009.114207
复制
发表时间：
2009
影响因子：
27.4
通讯作者：
N. Sattar
中科院分区：
文献类型：
--
作者：
M. Peters;P. Watt;L. Cherry;P. Welsh;Eric Henninger;B. Dijkmans;I. McInnes;M. Nurmohamed;N. Sattar
背景脂联素是一种抗炎和潜在的抗动脉粥样硬化分子。最近的一些报告表明，肿瘤坏死因子α(肿瘤坏死因子α)阻断治疗会增加循环中的脂联素水平，但数据稀少且不一致。方法采用安慰剂双盲对照研究方法，对12 6例银屑病患者和171例类风湿关节炎患者进行阿达单抗治疗前后的对照研究，观察肿瘤坏死因子α阻断治疗对脂联素的影响。结果尽管预期脂联素与性别和基线高密度脂蛋白胆固醇和甘油三酯相关，但在接受肿瘤坏死因子α阻断治疗的两组中，脂联素水平并没有随时间改变。联合用药组和安慰剂组的脂联素绝对值分别为−0.23±4.6μg/ml和0.28±3.23μg/ml(与安慰剂组比较，p=0.6)。结论肿瘤坏死因子α阻断治疗对自身免疫性疾病患者循环脂联素水平无明显影响。
Background Adiponectin is an anti-inflammatory and potentially antiatherogenic molecule. Some recent reports suggest that tumour necrosis factor α (TNFα) blockade therapy increases circulating adiponectin levels, but data are sparse and inconsistent. Methods Data from a double-blind placebo controlled study of onercept in 126 patients with psoriatic arthritis (PsA) and from pre- and post-adalimumab treatment in 171 patients with rheumatoid arthritis (RA) were used to examine the effect of TNFα blockade therapy on adiponectin. Results Despite expected associations of adiponectin with gender and baseline high-density lipoprotein cholesterol and triglyceride, adiponectin levels did not change over time with TNFα blockade therapy in either group. The mean±SD absolute change in adiponectin levels was −0.23±4.6 μg/ml in patients with PsA treated with combined onercept 50 mg and onercept 100 mg (vs placebo, p=0.60) and 0.28±3.23 μg/ml in patients with RA treated with adalimumab (vs baseline, p=0.66). Conclusion These results do not support a significant effect of TNFα blockade therapy on circulating adiponectin levels in patients with autoimmune disease.